148 related articles for article (PubMed ID: 35441782)
1. Clinical and histopathological improvement of scleromyxedema-induced microstomia after hyaluronidase injection.
Akaslan TÇ; Yıldız P; Onsun N
J Cosmet Dermatol; 2022 Oct; 21(10):4319-4322. PubMed ID: 35441782
[TBL] [Abstract][Full Text] [Related]
2. Intravenous immunoglobulin therapy for scleromyxedema: a case report and review of literature.
Sroa N; Campbell S; Bechtel M
J Drugs Dermatol; 2010 Mar; 9(3):263-5. PubMed ID: 20232589
[TBL] [Abstract][Full Text] [Related]
3. Intravenous gammaglobulin and thalidomide may be an effective therapeutic combination in refractory scleromyxedema: case report and discussion of the literature.
Efthimiou P; Blanco M
Semin Arthritis Rheum; 2008 Dec; 38(3):188-94. PubMed ID: 18221985
[TBL] [Abstract][Full Text] [Related]
4. Managing scleromyxedema with intravenous immunoglobulin: acute worsening of scleromyxedema with biclonal gammopathy.
Manousaridis I; Loeser C; Goerdt S; Hassel JC
Acta Dermatovenerol Alp Pannonica Adriat; 2010 Dec; 19(4):15-9. PubMed ID: 21390475
[TBL] [Abstract][Full Text] [Related]
5. Treatment of scleromyxedema and the dermatoneuro syndrome with intravenous immunoglobulin.
Rey JB; Luria RB
J Am Acad Dermatol; 2009 Jun; 60(6):1037-41. PubMed ID: 19249127
[TBL] [Abstract][Full Text] [Related]
6. [Atypical scleromyxedema with a granulomatous histological pattern and delayed sclerosis].
de Cambourg G; Goussot R; Wettlé C; Cribier B
Ann Dermatol Venereol; 2016 May; 143(5):382-6. PubMed ID: 26969478
[TBL] [Abstract][Full Text] [Related]
7. Scleromyxedema with multiple systemic involvement: Successful treatment with intravenous immunoglobulin.
Kim S; Park TH; Lee SM; Kim YH; Cho MK; Whang KU; Kim HS
Dermatol Ther; 2020 May; 33(3):e13378. PubMed ID: 32250023
[TBL] [Abstract][Full Text] [Related]
8. Scleromyxedema in a 21 year old female patient with acute lymphoblastic leukemia: a case report.
Rabee H; Tayem L; Gharbeyah M; Abugaber D
BMC Dermatol; 2020 Dec; 20(1):18. PubMed ID: 33276772
[TBL] [Abstract][Full Text] [Related]
9. [Efficacy of intravenous immunoglobulin in Arndt-Gottron scleromyxedema].
Lopez L; Wierzbicka-Hainaut E; Villers A; Guillet G
Ann Dermatol Venereol; 2009 Apr; 136(4):330-6. PubMed ID: 19361699
[TBL] [Abstract][Full Text] [Related]
10. An unusual presentation of scleromyxedema as inflammatory myopathy.
Vysakha KV; Poyuran R; Nair SS; Nair M
Acta Myol; 2019 Mar; 38(1):13-16. PubMed ID: 31309176
[TBL] [Abstract][Full Text] [Related]
11. Long-Term Efficacy of Treatment with Intravenous Immunoglobulin in Scleromyxedema.
Baglama Š; Trčko K
Acta Dermatovenerol Croat; 2020 Jul; 28(1):24-28. PubMed ID: 32650847
[TBL] [Abstract][Full Text] [Related]
12. Case report: Scleromyxedema associated with a monoclonal gammapathy: Successful treatment with intravenous immunoglobulins.
Wang SS; Chen QY; Xiang LH
Front Immunol; 2022; 13():1099918. PubMed ID: 36713453
[TBL] [Abstract][Full Text] [Related]
13. Scleromyxedema without paraproteinemia.
Abarzúa AA; Giesen LF; Sandoval MO; González SB
Int J Dermatol; 2014 Aug; 53(8):971-4. PubMed ID: 24527753
[TBL] [Abstract][Full Text] [Related]
14. [Good response of scleromyxedema and dermato-neuro syndrome to treatment with intravenous immunoglobulins].
Bielsa I; Benvenutti F; Guinovart RM; Ferrándiz C
Actas Dermosifiliogr; 2012 May; 103(4):317-20. PubMed ID: 21917233
[TBL] [Abstract][Full Text] [Related]
15. [Monoclonal immunoglobulin (M-Ig) and skin diseases from the group of mucinoses--scleredema adultorum Buschke and scleromyxedema. Description of four cases and an overview of therapies].
Adam Z; Szturz P; Krejčí M; Vašků V; Pour L; Michalková E; Ševčíková S; Čermáková Z; Veselý K; Vaníček J; Pourová E; Král Z; Mayer J
Vnitr Lek; 2015 Dec; 61(12):1072-87. PubMed ID: 26806503
[TBL] [Abstract][Full Text] [Related]
16. Scleromyxedema: a case series highlighting long-term outcomes of treatment with intravenous immunoglobulin (IVIG).
Blum M; Wigley FM; Hummers LK
Medicine (Baltimore); 2008 Jan; 87(1):10-20. PubMed ID: 18204366
[TBL] [Abstract][Full Text] [Related]
17. Characterization of circulating myeloma tumor cells by next generation flowcytometry in scleromyxedema patient: a case report.
Taha RY; Hasan S; Ibrahim F; Chantran Y; Sabah HE; Sivaraman S; Bozom IA; Sabbagh AA; Garderet L; Omri HE
Medicine (Baltimore); 2020 Jul; 99(27):e20726. PubMed ID: 32629647
[TBL] [Abstract][Full Text] [Related]
18. Plasma cell-directed therapies in monoclonal gammopathy-associated scleromyxedema.
Mahévas T; Arnulf B; Bouaziz JD; Livideanu CB; Osio A; Servy A; Cribier B; Sassolas B; Jachiet M; Michel L; Aucouturier P; Lipsker D; Frances C; Sbidian E; Rybojad M; Descamps V; D'Incan M; Humbert P; Beylot-Barry M; Passeron T; de Moreuil C; Taha RY; Hermine O; Dupuy A; Barbarot S; Debarbieux S; Carpentier O; Brault F; Schmutz JL; Thomas-Beaulieu D; Modiano P; Zarnitsky C; Lifermann F; Baubion E; Limal N; Le Bras F; Le Moigne M; Tauber M; Talbot A; Prud'homme R; Peltier S; De Masson A; Battistella M; Bagot M; Mékinian A; Fain O
Blood; 2020 Apr; 135(14):1101-1110. PubMed ID: 32027747
[TBL] [Abstract][Full Text] [Related]
19. Combination oral prednisone and intravenous immunoglobulin in the treatment of scleromyxedema.
Majeski C; Taher M; Grewal P; Dytoc M; Lauzon G
J Cutan Med Surg; 2005 Jun; 9(3):99-104. PubMed ID: 16392012
[TBL] [Abstract][Full Text] [Related]
20. Scleromyxedema.
Hoffmann JHO; Enk AH
J Dtsch Dermatol Ges; 2020 Dec; 18(12):1449-1467. PubMed ID: 33373143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
